Catalyst Biosciences


nassim usman spacer

Nassim Usman, Ph.D., President and Chief Executive Officer

Dr. Usman is currently President and CEO and a member of the Board of Directors at Catalyst Biosciences. Dr. Usman joined Catalyst from Morgenthaler Ventures, where he is a Venture Partner. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc. (Nasdaq:RNAI – acquired by Merck NYSE:MRK) from 2004 to 2005 and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals (Nasdaq:RZYM), including VP of R&D and Chief Scientific Officer, from 1992 to 2004. During his industrial career Dr. Usman has entered several drugs into clinical development, completed multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to moving into the biotechnology industry in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and 130 patents and applications. Dr. Usman serves on the Boards of Mosaic Biosciences, Principia Biopharma and Osprey Pharmaceuticals, is a past director of Archemix Corporation (Cambridge, MA) and atugen AG (now Silence Therapeutics, LSE/AIM:SLN) and served on the SABs of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation he developed a method for the solid-phase synthesis of RNA that is widely used in science and in a marketed RNA product (Macugen™).

edwin madison  

Edwin L. Madison, Ph.D., Chief Scientific Officer

Dr. Madison received a Ph.D. in biochemistry from University of Texas - Southwestern Medical Center (UTSWC) in 1990. Following graduation, Dr. Madison accepted a faculty position at UTSWC with joint appointments in the Departments of Biochemistry and Internal Medicine. Dr. Madison then moved to The Scripps Research Institute as an Associate Professor of Vascular Biology. Prior to moving to Catalyst Biosciences, Dr. Madison was Vice President of Biological Research at Dendreon San Diego and Dendreon Corporation, Professor of Vascular Biology at the Torrey Pines Institute for Molecular Studies, and Adjunct Professor of Vascular Biology at The Scripps Research Institute. Dr. Madison has achieved an international reputation in the fields of serine protease and serpin basic research, and he is one of the lead inventors of a currently marketed protease therapeutic agent.


Fletcher Payne, CFO

Fletcher Payne has spent over 20 years helping life science companies achieve their business goals. In his role as CFO, he has focused on raising capital, developing strategic financial plans, managing business growth, implementing corporate partnerships, managing business performance, and revenue management. His life science experience includes successful start-ups, IPOs, mergers, spin-outs, and working with R&D teams whose efforts have led to four products receiving FDA clearance. His company experiences include CytomX, Pathwork Diagnostics, Plexxikon, Rinat Neuroscience, Dynavax Technologies, Cell Genesys, Abgenix, Sun Micro Systems, and IBM. Mr. Payne is a graduate of the Walter A. Haas School of Business at the University of California, Berkeley.


Michael Keyoung, M.D., Ph.D., President, Catalyst Asia

Dr. Keyoung has more than 15 years of healthcare and life sciences experience through his role as physician, consultant, and investor. Dr. Keyoung joined Catalyst in 2013 from Burrill & Company, first round, Series A investor of Catalyst Biosciences. At Burrill & Company, Dr. Keyoung has served as Managing Director in Venture Capital and Private Equity and as Head of Burrill Pan-Asia. He has been involved in several successful private company investments such as Ferrokin Biosciences (acquired by Shire), oversaw public investments in the United States, Europe and Asia including Novadaq (NASDAQ:NVDQ) and Taiwan Liposome Company (GTSM:4152), and lead Pan-Asia transaction business. Previously, Dr. Keyoung was a co-founder of a life sciences healthcare investment partnership in New York. Dr. Keyoung also served as an advisor and consultant to leading life sciences venture capital firms, medical devices, pharma, and biotechnology companies. Dr. Keyoung was a Howard Hughes Medical Institute Research fellow and received his clinical surgical training at University of California, San Francisco and biomedical fellowship at Memorial Sloan Kettering Institute and Rockefeller University in New York. Dr. Keyoung performed preclinical drug discovery research for Aventis (now Sanofi-Aventis) and Merck while at Cornell and participated in translational clinical trials at leading academic centers. As a National Institute of Health-Medical Scientist Training Program scholarship recipient, Dr. Keyoung received both his Medical Doctorate and Ph.D. degrees in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center. Dr. Keyoung has served on the Board of Directors at New York County Medical Society and Board of Overseers at Cornell University Weill Medical School and on the boards of private biopharma companies and organizations in the United States and in Asia.